Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
Abstract | OBJECTIVE: METHODS: Patients (N = 878) were randomly assigned (4:1 ratio) to receive tapentadol IR (50 or 100 mg, q4-6h, p.o.) or oxycodone IR (10 or 15 mg, q4-6h, p.o.). Tapentadol IR was evaluated for tolerability over 90 days, tolerability relative to oxycodone IR, withdrawal symptoms, and pain intensity. This study was not placebo-controlled, which limited efficacy evaluations. RESULTS: In total, 849 intent-to-treat patients received tapentadol IR (n = 679) or oxycodone IR (n = 170), and among these, 391 patients (57.6%) in the tapentadol IR group and 86 patients (50.6%) in the oxycodone IR group completed the study. Gastrointestinal events, including nausea (18.4% vs 29.4%), vomiting (16.9% vs 30.0%), and constipation (12.8% vs 27.1%), were reported by 44.2% of patients receiving tapentadol IR and 63.5% of patients receiving oxycodone IR, respectively. Nervous system events, including dizziness (18.1% vs 17.1%), headache (11.5% vs 10.0%), and somnolence (10.2% vs 9.4%), were reported by 36.7% of patients receiving tapentadol and 37.1% of patients receiving oxycodone, respectively. Odds ratios ( tapentadol: oxycodone) showed that the incidences of somnolence and dizziness were similar; however, nausea, vomiting, and constipation were significantly less likely with tapentadol IR compared with oxycodone IR. The pattern of withdrawal symptoms suggests that drug tapering may not be necessary after tapentadol IR treatment of this duration. Pain intensity measurements showed similar efficacy for tapentadol and oxycodone. CONCLUSION: During this 90-day study, tapentadol IR was associated with improved gastrointestinal tolerability compared with oxycodone IR while providing similar pain relief. Trial registration information: NCT00364546.
|
Authors | Martin Hale, David Upmalis, Akiko Okamoto, Claudia Lange, Christine Rauschkolb |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 25
Issue 5
Pg. 1095-104
(May 2009)
ISSN: 1473-4877 [Electronic] England |
PMID | 19301989
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics
- Phenols
- Oxycodone
- Tapentadol
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Analgesics
(administration & dosage, adverse effects)
- Double-Blind Method
- Drug Administration Schedule
- Drug Compounding
- Female
- Humans
- Low Back Pain
(drug therapy)
- Male
- Middle Aged
- Models, Biological
- Osteoarthritis, Hip
(complications, drug therapy)
- Osteoarthritis, Knee
(complications, drug therapy)
- Oxycodone
(administration & dosage, adverse effects)
- Pain
(drug therapy, etiology)
- Phenols
(administration & dosage, adverse effects)
- Tapentadol
- Time Factors
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|